Table 1.
Characteristics of AML patients (18–60 y) according to UBTF status.
| Parameters | UBTF-TD AML 18–60 y | UBTF wild-type AML 18–60 y (ALFA-0702) |
|---|---|---|
| No. of patients | 57 | 593 |
| Age (y), median (IQR) | 36 (24–45) | 47 (37–54) |
| WBC (×109/L), median (IQR) | 3.55 (2–27.4) | 8.3 (2.6–32.9) |
| BM blasts (%), median (IQR) | 25 (20–63) | 60 (39–82) |
| BM morphology, n (%) | ||
| M0 | 0 | 28/467 (6%) |
| M1/M2 | 15/33 (45%) | 254/467 (54%) |
| M4/M5 | 0 | 169/467 (36%) |
| M6 | 14/33 (42%) | 14/467 (3%) |
| M7 | 0 | 2/467 (0%) |
| MRC | 4/33 (12%) | |
| Cytogenetics | ||
| Normal, n (%) | 38/57 (67%) | 329/563 (58%) |
| Trisomy 8, n (%) | 16/57 (28%) | 46/545 (8%) |
| Monosomy 5/del(5q), n (%) | 0 | 33/545 (6%) |
| Monosomy 7/del(7q), n (%) | 0 | 47/545 (9%) |
| Monosomy 17/del(17p), n (%) | 0 | 22/545 (4%) |
| Del(20q), n (%) | 0 | 14/545 (3%) |
| Del(12p), n (%) | 0 | 14/545 (3%) |
| Complex, n (%) | 0 | 67/545 (12%) |
| WT1 mutations, n (%) | 36/57 (63%) | 48/572 (8%) |
| Signaling mutations | ||
| FLT3-ITD, n (%) | 30/57 (53%) | 127/572 (22%) |
| FLT3-TKD, n (%) | 4/57 (7%) | 72/572 (13%) |
| NRAS, n (%) | 13/57 (23%) | 126/572 (22%) |
| KRAS, n (%) | 7/57 (12%) | 43/572 (8%) |
| PTPN11, n (%) | 6/57 (11%) | 32/572 (6%) |
| RIT1, n (%) | 6/57 (11%) | 19/572 (3%) |
| DNA-methylation gene mutations | ||
| DNMT3A, n (%) | 3/57 (5%) | 162/572 (28%) |
| TET2, n (%) | 5/57 (9%) | 74/572 (13%) |
| IDH1, n (%) | 3/57 (5%) | 53/572 (9%) |
| IDH2, n (%) | 3/57 (5%) | 74/572 (13%) |
| NPM1 mutations, n (%) | 0 | 208/572 (36%) |
| CEBPA double mutations, n (%) | 0 | 30/572 (5%) |
| TP53 mutations, n (%) | 0 | 39/572 (7%) |
| MDS-related gene mutations*, n (%) | 5/57 (9%) | 168/572 (29%) |
| ELN 2022 risk | ||
| Favorable | 0 | 143/548 (26%) |
| Intermediate | 52/57 (91%) | 157/548 (29%) |
| Adverse | 5/57 (9%) | 248/548 (45%) |
*MDS-related genes: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2.
These data refer to only 57 of the 59 patients with UBTF-TDs (the 2 patients over 60 years of age were excluded for comparisons).
BM bone marrow, IQR interquartile range, MRC myelodysplastic-related changes, WBC white blood cell count.